title: Treatment of diffuse proliferative lupus nephritis: an Indian experience.
abstract: BACKGROUND
  Immunosuppressive therapy has improved the prognosis in lupus nephritis. However, infectious complications may contribute to morbidity. There is also debate on the best form of therapy. We, therefore, compared the results of two different forms of therapy.
  
  
  METHODS
  Twenty-nine patients diagnosed to have diffuse proliferative lupus nephritis were followed up over 54 months. The treatment consisted of azathioprine (1.5 mg/kg/day) or pulse intravenous cyclophosphamide (500 mg/m2 body surface area monthly) along with prednisolone (2 mg/kg on alternate days).
  
  
  RESULTS
  Seventeen patients received azathioprine (group A) and 12 received cyclophosphamide (group B). The mean (SD) follow up in groups A and B were 54.35 (33.6) and 52 (35.8) months, respectively. Apart from the higher number of males in group B, both groups were comparable for age, presence of hypertension, renal function, 24-hour urinary protein excretion and composite scores for histological activity and chronicity indices (p > 0.05). The renal survival estimated by the Kaplan-Meier method was similar in both groups (p > 0.05). Four patients had renal failure requiring replacement therapy in group A and 3 in group B. Major infective episodes were more common in group B than in group A (p = 0.03).
  
  
  CONCLUSIONS
  Azathioprine was as effective as pulse intravenous cyclophosphamide in preserving renal functions up to 54 months. Major infective episodes were more common with pulse intravenous cyclophosphamide.
authors.affiliation: Department of Nephrology, Christian Medical College and Hospital, Vellore, Tamil Nadu, India.
authors.forename: M A
authors.initials: MA
authors.lastname: Abraham
authors.forename: A
authors.initials: A
authors.lastname: Korula
authors.forename: K N
authors.initials: KN
authors.lastname: Arun
authors.forename: K
authors.initials: K
authors.lastname: Jayakrishnan
authors.forename: G T
authors.initials: GT
authors.lastname: John
authors.forename: P P
authors.initials: PP
authors.lastname: Thomas
authors.forename: C K
authors.initials: CK
authors.lastname: Jacob
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000627:therapeutic use*; D016009:Chi-Square Distribution; D003520:Cyclophosphamide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007194:India; D008181:Lupus Nephritis / Q000188:drug therapy*; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D000893:Anti-Inflammatory Agents; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D011239:Prednisolone; D001379:Azathioprine